AIM ImmunoTech Inc
AIM
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.38M
Close$
$-0.29
172.1% downside
Current Fair Value
172.1% downsideOvervalued by 172.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.38 Million |
|---|---|
| Enterprise Value | $-4,074,503.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-8.62 |
| Beta | 1.24 |
| Outstanding Shares | 4,351,449 |
Return
| Return on Equity | -624.75% |
|---|---|
| Return on Assets | -154.64% |
| Return on Invested Capital | -339.84% |
Valuation & Multiples
| P/E Ratio | -0.13 |
|---|---|
| PEG | 0.72 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -43.35 |
| Enterprise Value to EBIT | 0.49 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.09 |
| Debt to Equity | 0.17 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 21, 2026
EPS Estimate
$-0.37
Average shareholder expectationRevenue Estimate
$20,781
Average shareholder expectationNext Earnings Call
Expected Date
August 13, 2026
EPS Estimate
$-0.17
Average shareholder expectationRevenue Estimate
$100,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 4.04%▲ 4.04% |
|---|---|
| Total Invested | $102,813 |
| Investors Holding | 18▲ 18.00% |
ESG Score
No data
About AIM ImmunoTech Inc
CEO: Thomas Equels